IgA nephropathy in patients with congenital C9 deficiency  by Yoshioka, Kazuo et al.
Kidney International, Vol. 42 (1992), PP. 1253—1258
IgA nephropathy in patients with congenital C9 deficiency
KAZUO YOSHIOKA, TSUKASA TAKEMURA, N0RIHIsA AKANO, MITSURU OKADA, KAZURO YAGI,
SUNAO MAKI, SHINYA INAI, HIR0N0Bu AKITA, YASUSHI KOITABASHI,
and YASUO TAKEKOSHI
Department of Pediatrics, Kinki University School of Medicine, and Department of Clinical Pathology, Osaka Medical College, Osaka;
Department of Pediatrics, Yamato City Hospital, Yamato-city; Department of Pediatrics, St. Marianna University School of Medicine,
Kawasaki; and Department of Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan
IgA nephropathy in patients with congenital C9 deficiency. The clini-
cal, histologic, and immunopathological findings of three young Japa-
nese males with congenital C9 deficiency and primary IgA nephropathy
are reported. The C9 deficiency was discovered either through mass
complement screening, or when low hemolytic activity for CH5O and
normal C3 levels were detected in plasma. Hematuria and proteinuria
were detected at the age of 8 or 9 years as a result of annual urinary
screening tests for school children. Renal biopsy showed focal and
segmental mesangial proliferation with small epithelial crescents in one
patient, and mild, diffuse mesangial proliferation in two. IgA and C3
were deposited predominantly in the mesangial area, and staining for C9
was negative in these patients. Electron microscopy revealed electron
dense deposits predominantly in mesangial and paramesangial zones.
Immunohistochemical staining in renal biopsy tissues from two patients
showed mesangial staining for C5, C8, and S-protein, but staining for
C5b-9 neoantigen was completely negative. These results show that the
formation of C5b-9 complex is not essential for the induction of human
IgA nephropathy, and also for the proliferation of mesangial and even
parietal epithelial cells.
IgA nephropathy, in which renal failure and progression to
end-stage kidney disease are not rare, has been recognized
worldwide as the most common form of glomerulonephritis in
humans [1]. Complement is considered to be one of the factors
contributing to the severity and progression of the disease.
Renal biopsies from patients with IgA nephropathy typically
show glomerular deposits of C3 and also its breakdown prod-
uct, C3d [2, 3]. In experimental IgA nephropathy in mice,
glomerular C3 seems to promote hematuria [41.
In addition to its capacity to produce inflammatory tissue
injury through the generation of chemotactic C5a fragments or
C3b receptor-mediated immune adherence mechanisms, com-
plement is also known to have cytolytic activity; this is due to
a surface-bound complex of the terminal complement C5b-9,
the membrane attack complex (MAC) [5]. Studies in animals
have established that the terminal complement complex directly
mediates glomerular injury in several models of experimental
nephritis [6]. The development of proteinuria was almost com-
pletely prevented in membranous nephropathy in C6-deficient
[7] and in C6-depleted [8] animals and also in the heterologous
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phase of antiglomerular basement membrane nephritis in C6-
deficient rabbits [9]. C8-dependent proteinuria and MAC-
induced cytotoxicity of the glomerular visceral epithelial cells
were demonstrated in rat membranous nephropathy [10, 11].
Studies of experimental IgA nephritis in mice suggest that C5,
and therefore C5b-9, are not necessary for hematuria [12]. In
recent years, another activity of C5b-9 complex has also
attracted increasing interest. C5b-9, in sublytic doses, can
stimulate various cells, resulting in the release of inflammatory
mediators. When cultured mesangial cells were incubated with
sublytic doses of activated C5b-9, the release of eicosanoids,
interleukin 1, tumor necrosis factor, and oxygen radicals was
observed [6, 131.
Immunofluorescent studies in nephritic human tissues, in-
cluding those with IgA nephritis, have shown the presence of
MAC neoantigen or polymerized C9 in glomerular immune
deposits [3, 14—16]. These observations provide only indirect
evidence for the nephrotoxic role of MAC in mediating glomer-
ular injury in humans. Since the complement regulatory com-
ponent, S-protein, is invariably co-localized with C5b-9 depo-
sition [17—19], it is questionable whether the MAC found in
human nephritic tissues is physiologically active, as is the MAC
demonstrated experimentally in animal models. Investigation of
the combination of an inherited terminal complement deficiency
and glomerulonephritis in a single patient, although such pa-
tients are extremely rare, could elucidate the pathogenetic role
of MAC. In this report, we describe three patients with con-
genital C9 deficiency and primary IgA nephropathy. Our obser-
vations indicate that IgA nephropathy can be induced when
there is terminal complement component deficiency.
Methods
The urinary abnormalities in the patients described here were
detected as a result of urinary screening, which is performed
annually, nationwide, in elementary school children in Japan
[20]. As the first screening test, urine samples collected at home
were tested with dipsticks. In children whose samples were
positive for occult blood, urinalysis was repeated and a red
blood cell count was carried out microscopically.
Sera sent from hospitals throughout Japan to a laboratory
center were screened by sensitive assay for low hemolytic
activity of whole complement (CH5O), as described previously
[21, 22]. Sera showing no hemolysis or only faint hemolysis
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Table 1. Clinical and laboratory findings in three patients with congenital C9 deficiency and IgA nephropathy
Table 2. Morphologic findings in renal biopsy specimens
Histologic Mesangial Crescents Glomeruli
pattern proliferation % scierosed %
-—
24*** 0FSP mild-moderate
2 DMP mild 0
3 DMP mild 0 0
EM
Site of
EDDb Immunofluorescence'
mes, parames
(subepi, subendo)
0 mes (subendo)
Abbreviations: EM, electron microscopy; EDD, electron dense deposits; FSP, focal and segmental proliferation, DMP, diffuse mesangial
proliferation.
The results of immunofluorescent staining for other complement components and S-protein in glomeruli were: Patients 1 and 3; CS positive,
C8 positive, C9 negative, C5b-9 neoantigen negative, and S-protein positive and Patient 2: C9 negative.
b Sites of EDD are indicated by mes (mesangium), parames (paramesangial zone), subepi (subepithelial zone) and subendo (subendothelial zone).
Sites in parenthesis indicate EDD sites which were less frequently seen.
Small epithelial crescents were observed in 5/21 (24%) of glomeruli.
were further examined for protein concentration and hemolytic
activity of C9 and other complement components. C9 hemolytic
activity was determined with glucose gelatin veronal buffer and
sensitized sheep erythrocytes bearing guinea pig C8 sites, as
described elsewhere [23]. The activities of the other compo-
nents were determined using appropriate intermediate cells and
reagents [24, 25]. Protein concentrations of C3-C9 in serum
were measured by single radial immunodiffusion or laser nephe-
lometry, using appropriate antibodies monospecific to each
complement component [21, 22].
The kidney tissues in this study were obtained by percutane-
ous needle biopsy. For light microscopic examination, tissue
was fixed in 10% buffered formalin and embedded in paraffin.
This sections were stained with hematoxylin and eosin, periodic
acid-Schiff, and methenamine silver. Tissues frozen in liquid
nitrogen were cut in 4 •m thick sections, and direct and indirect
immunofluorescence i1icroscopy was performed. IgG, IgA,
1gM, C3, and C4 were directly stained, using fluorescein-
labeled IgG fractions of goat antisera to human IgG, IgA, 1gM,
C3, and C4 (Cappel, Malvern, Pennsylvania, USA), respec-
tively. CS, C8, C9, CSb-9, and S-protein were stained by an
indirect method, using rabbit antisera to human C5, C8, and C9
(Binding Site, Birmingham, UK), mouse monoclonal antibody
to a neoantigen of the C9 portion of C5b-9 complex (PolyC9-
MA, mouse IgGI, provided by Dr. A. F. Michael, University of
Minnesota) [14], and monoclonal and polyclonal antibodies
specific to S-protein (Chemicon, El Segundo, California, USA),
respectively, with the appropriate secondary antibody conju-
gated with fluorescein, as described previously [26].
Kidney tissues were examined by conventional electron
microscopy. Kidney tissue from patient 3 was studied by
immunoelectron microscopy to localize IgA and S-protein.
Postembedding staining with colloidal gold was performed as
described previously [27]. Ultra-thin sections were incubated
with IgG fractions of goat antisera to human IgA (Cappel), or
polyclonal and monoclonal antibody to S-protein. The appro-
priate secondary antibody, conjugated with colloidal gold (par-
ticle size: 10 nm), was then applied. The sections were stained
with uranyl acetate and viewed under an electron microscope.
Results
Patients
The clinical and laboratory findings of the three patients are
summarized in Table 1. These three patients were all males and
were not related; proteinuria and hematuria were found when
they were 8 or 9 years of age. C9 deficiency was detected in
patients 1 and 2 through mass complement screening. In patient
3, C9 level was determined because low hemolytic activity was
noted on CH5O assay, and he had normal C3 and C4 levels. In
Patient Sex
Age at
histological
diagnosis
years
Initial
manifes-
tation
Duration
before
biopsy
Duration
of
follow-
Proteinuria
(g/day) at
diagnosis!
Hematuria
(RBC counts
per HPF) at
Serum
creatinine
(pmol/Iiter) at
Complement
levela
mg/a'!
months up year latest diagnosis/latest diagnosis/latest C3 C9
I. M.T. M 9 asymptomatic
P&H
3 9 2.5/<0.l many!S—6 38/46 86 ND
2. OH. M 9 asymptomatic
P&H
1 8 l.7/<0.l many!0—l 46/53 68 ND
3. K.A. M 8 asymptomatic
P&H
7 3 0.2/<0.l many!l7—20 31/38 83 ND
Abbreviations are: HPF, high power field; P&H, proteinuria and hematuria; ND, not detected.
a Normal range: C3, 60 to 116 mg/dl; C9, 2.7 to 7.3 mg!dl
Patient
Light microscopy
mes, parames
(subepi. subendo)
IgA; IgG; C3
IgA; IgG; 1gM;
C3
IgA; C3C
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Fig. 1. Light micrographs of renal biopsy tissues obtained from patients 1 and 3 (Periodic acid-Schiff staining. A and B: x200). A. Patient 1.
Olomeruli showing hypercellularity in segmental region. Small epithelial crescent is present in one glomerulus (left). B. Patient 3. Two glomeruli
showing mild increases in mesangial cells.
all three patients, C9 hemolytic activity was below 0.1% of
normal levels and C9 protein concentration was undetectable.
Other complement components (Cl -C8) were present at normal
levels when assayed by the functional hemolytic test. Protein
levels of C3-C8 were also normal. At the time of renal biopsy,
microscopic hematuria was present in all three patients; the
degree of proteinuria was moderate in patients I and 2, and mild
in patient 3. In all three patients, physical and laboratory
examinations, including renal function tests and blood pressure,
were within normal range. Complications other than C9 defi-
ciency and nephritis were not found. Patient 3 had a past history
of meningitis (the causative organism was not identified) at age
3 months, with full recovery. C9 levels were examined in the
family members of patient 3, revealing that this patient was
homozygous.
Renal pathology/immunopathology
The histologic findings of the renal biopsy specimens are
summarized in Table 2. Light microscopy of the renal biopsy
specimens showed focal and segmental mesangial proliferation
in patient 1 and mild, diffuse mesangial proliferation in patients
2 and 3 (Fig. I). In patient I, small epithelial crescents were
found in 5 of a total 21 glomeruli (24%) examined, and adhe-
sions of the glomerular tuft to Bowman's capsule were found in
5 glomeruli (24%). Electron microscopic studies carried out in
the three patients revealed that electron dense deposits were
frequently present within the mesangial matrix and in the
paramesangial zone, and, to a lesser extent, in the subendo-
thelial and subepithelial areas. No alterations were found in the
glomerular basement membranes in any cases. Direct immuno-
fluorescent staining showed a dominant deposition of IgA in the
mesangial area (Fig. 2A). In all three patients, staining for C3
was positive in the mesangium (Fig. 2B), and staining for C9
was completely negative in glomeruli. IgG was deposited in
patients 1 and 2.
Further immunopathologic studies were carried out on renal
specimens obtained from patients I and 3. Immunofluorescence
for CS and C8 were positive in the mesangial area, their
localization being similar to that of C3. Staining for C5b-9
neoantigen was entirely negative in these tissues (Fig. 2C).
S-protein was stained diffusely in the mesangium and weakly
along the glomerular capillary walls (Fig. 2D). Immunoelectron
microscopy with colloidal gold staining was carried out using
the tissue from patient 3; IgA and S-protein were localized to
mesangial and paramesangial electron-dense deposits (Fig. 3).
Small amounts of S-protein were also distributed in the mesan-
gial matrix and in the glomerular basement membrane.
Clinical course
The diagnosis of IgA nephropathy was made in all three
patients consistent with the following criteria: (1) there was no
evidence of systemic lupus erythematosus, Henoch-Schonlein
purpura nephritis, or liver disease, according to the history,
physical examination, or laboratory investigations; (2) light
microscopy of the renal tissues showed mesangial proliferation;
and (3) immunofluorescent study demonstrated dominant IgA
deposition with mesangial distribution. These patients have
now been followed up for 3, 8, and 9 years, respectively,
without any specific drug therapy. Renal function and blood
pressure have remained normal in all three. At the latest
check-up. proteinuria was negative or trace-positive in all three
patients, and hematuria has resolved in patients 1 and 2.
Discussion
Complement screening, using sera from healthy blood donors
and sera sent from hospitals for CH5O assay, has revealed a
relatively high incidence of C9 deficiency in Japan [21, 22].
C9-deficient individuals may be healthy or they may suffer from
various types of diseases, such as infections, autoimmune
diseases, and glomerulonephritis, the occurrence of which is
now thought to be incidental. Based on family studies in 20
blood donors with C9 deficiency, an autosomal codominant trait
has been proposed as the mode of inheritance [22]. Three
patients with congenital C9 deficiency and IgA nephropathy,
including two who have been listed in a Table in a previous
paper [21], have been described in this report.
To date, there is no definite evidence for the role of terminal
complement components in the pathogenesis of IgA nephrop-
athy either in experimental animals or in humans. Studies by
Rauterberg et al [15], showing a correlation between MAC
:H ,' .4 t4'*j'j; Z1-- -' :' .4. pw1rstsr.4\?.: 'VA'fl•"S'
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Fig. 2. hnmunofluorescent micrographs of tissue sections from patient 3, stained with anti-IgA antibody (A), anti-3 antibody (B), monoclonal
antibody to C5b-9 neoantigen (C) and monoc/onal antibody to S-protein (D) (A—D: x400). There is diffuse, mesangial staining of IgA (A) and C3
(B), with occasional granular staining alone the glomerular capillary walls. The vascular pole (V) of the glomerulus is also positive for C3. Staining
for C5b-9 is completely negative (C). Staining for S-protein is diffuse in the mesangium and weak and linear along the glomerular basement
membrane (arrow) (D). V; vascular pole of glomerulus, G; glomerulus.
deposition and proteinuria in patients with IgA nephropathy,
indirectly indicate that formation of MAC may contribute to the
progression of this disease, The relatively high frequency of C9
deficiency and the higher detection rate of IgA nephropathy
resulting from urine screening in Japan provided us with a
valuable opportunity to observe the natural history of this type
of nephritis in genetic C9-deficient patients. These observations
could help to clarify the nephritogenicity of MAC in human IgA
nephropathy, this condition being analogous to the experimen-
tal nephritis induced in rabbits genetically deficient in a terminal
component of complement [7, 9].
The present study has definitely shown that C9, and therefore
C5b-9 are not necessary for the development of hematuria and
proteinuria in human IgA nephropathy. All three patients
showed overt hematuria and proteinuria, although these were
often transient. Renal biopsy revealed mesangial proliferation
in three patients, and epithelial crescents in one. Mesangial
deposition of IgA along with C3, as well as mesangial electron
dense deposits were demonstrated in the tissues of the three
patients. As predicted by the relatively mild morphologic
changes in these patients, proteinuria was transient, and renal
function and blood pressure remained normal during the fol-
low-up period. The histologic (marked mesangial proliferation,
glomerular scierosis/hyalinosis, and interstitial inflammation)
and clinical features (persistent massive proteinuria, hyperten-
sion, and decreased renal function), which are regarded as
indicative of the progressive course of human IgA nephropathy
[2], were not found in any of these patients. Thus, it is possible
that, in genetic C9-deficient patients, defects in local MAC
formation may he associated with a rather mild course of IgA
nephropathy. The examination of larger numbers of patients
with IgA nephropathy and a coexisting deficiency of terminal
complement components could further confirm the nephrotoxic
role of MAC in IgA nephropathy, and could also provide
information regarding the likelihood of C9 deficiency and IgA
nephropathy occurring by chance alone or via a more direct
linkage. Recently, a different group in Japan [28] briefly re-
ported another patient (19-year-old male) with IgA nephropathy
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co-deposition of C5b-9 and S-protein in immune deposits found
in nephritic tissues from patients with normal C9 levels might
not be a real complex; it could be merely an apparent coexis-
tence.
Thus, these findings demonstrate, for the first time, that the
formation of terminal complement complex is not essential for
the development of human IgA nephropathy. Defects in local
MAC formation might explain why the clinical course of
nephritis in these patients is mild and stable.
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Fig. 3. immunoelectron micrograph of a portion of the glomerular
mesangium (patient 3), stained with rabbit antibody to human S-protein
and goat anti-rabbit IgG conjugated with colloidal gold. Gold particles
are present in abundant amounts within the electron dense deposits,
and sparsely in the mesangial matrix (x 12,500). The horizontal bar
equals 1.0 tm. M; mesangial area, US; urinary space.
and inherited C9 deficiency, whose clinical and histologic
features are mild.
As indicated by negative immunofluorescence results for C9
and C5b-9 neoantigen in the kidney tissues, the complete C5b-9
complex cannot be formed in these patients. There is a possi-
bility that C5b-8 is involved in this glomerular pathophysiology,
via a mechanism of cell membrane lysis [291 or non-lytic,
biological effects on glomerular cells [30]. However, evidence
suggests that the formation of C5b-9, rather than C5b-8, is more
critical to cell damage in humans. For example, in C9-deficient
sera, the lysis of erythrocytes proceeds at a remarkably reduced
rate, compared to that in normal of C9-repleted C9-deficient
sera [25]. Clinically, only mild hemolysis was noted in a
congenital C9-deficient patient in whom the condition was
complicated by paroxysmal nocturnal hemoglobinuria [311.
This patient experienced gross hemolysis only after receiving
postoperative transfusions of whole blood. Sublytic doses of
C5b-8, which can stimulate nucleated cells to release several
mediators, might affect the metabolism of glomerular cells [30],
but the precise role of low, sublethal doses of C5b-8 in vivo is
still unclear.
S-protein, which is identical to vitronectin, is normally
present in the glomerular basement membrane and mesangial
matrix [19]. Human IgA nephropathy is among the first diseases
recognized to have co-deposition of C5b-9 and S-protein in
immune deposits [17—191. S-protein interferes with the biologic
effects of C5b-9 through inhibiting its insertion into the cell
membrane [32, 33]. Our observation of renal tissues from two of
C9-deficient patients suggests that S-protein is deposited in the
form of SC5b-8, since there was mesangial co-staining of C5, C8
and S-protein. Our immunopathologic studies also indicate
another possibility, namely, that S-protein can accumulate in
immune deposits without accompanying C5b-9 deposition. The
Reprint requests to Kazuo Yoshioka, M.D., Department of Pediat-
rics, Kinki University School of Medicine, 377-2, Ohno-higashi, Osaka-
sayama 589, Japan.
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